Julia McNabb-Baltar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatitis | 16 | 2024 | 1097 | 4.410 |
Why?
|
| Pancreatitis, Chronic | 8 | 2024 | 288 | 3.990 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2022 | 86 | 1.470 |
Why?
|
| Lipase | 4 | 2024 | 324 | 1.090 |
Why?
|
| Cholangitis | 2 | 2013 | 111 | 0.800 |
Why?
|
| Acute Disease | 14 | 2024 | 7237 | 0.720 |
Why?
|
| Abdominal Pain | 5 | 2024 | 1070 | 0.690 |
Why?
|
| Colonoscopy | 3 | 2019 | 1396 | 0.620 |
Why?
|
| Hypertriglyceridemia | 1 | 2020 | 293 | 0.560 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2022 | 452 | 0.540 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 3805 | 0.510 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2023 | 2423 | 0.500 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 1738 | 0.460 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 1779 | 0.450 |
Why?
|
| Biological Products | 1 | 2023 | 912 | 0.450 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2013 | 506 | 0.450 |
Why?
|
| Emergency Service, Hospital | 8 | 2024 | 7871 | 0.440 |
Why?
|
| Hospitalization | 6 | 2019 | 10704 | 0.430 |
Why?
|
| Patient Readmission | 3 | 2023 | 3269 | 0.400 |
Why?
|
| Office Visits | 1 | 2016 | 593 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 1201 | 0.390 |
Why?
|
| Colonic Polyps | 1 | 2016 | 553 | 0.370 |
Why?
|
| Colitis, Ulcerative | 1 | 2023 | 1921 | 0.370 |
Why?
|
| Hospital Mortality | 3 | 2021 | 5293 | 0.360 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2023 | 173 | 0.360 |
Why?
|
| Crohn Disease | 1 | 2023 | 2279 | 0.360 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 2948 | 0.340 |
Why?
|
| Patient Admission | 2 | 2018 | 1365 | 0.340 |
Why?
|
| Life Style | 1 | 2020 | 3904 | 0.320 |
Why?
|
| Hepatitis B | 1 | 2014 | 702 | 0.320 |
Why?
|
| Smoking Cessation | 1 | 2020 | 2056 | 0.320 |
Why?
|
| Multivariate Analysis | 7 | 2022 | 12043 | 0.300 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 4025 | 0.290 |
Why?
|
| Drainage | 1 | 2013 | 1156 | 0.290 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2023 | 3752 | 0.290 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 1351 | 0.280 |
Why?
|
| Bone Density | 1 | 2020 | 3548 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2022 | 7960 | 0.270 |
Why?
|
| Vitamin D | 1 | 2020 | 3302 | 0.270 |
Why?
|
| Retrospective Studies | 15 | 2023 | 80566 | 0.270 |
Why?
|
| Length of Stay | 5 | 2023 | 6418 | 0.260 |
Why?
|
| Cesarean Section | 1 | 2014 | 1396 | 0.250 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 4416 | 0.250 |
Why?
|
| Diarrhea | 2 | 2022 | 1317 | 0.230 |
Why?
|
| Cost of Illness | 1 | 2014 | 1935 | 0.230 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 2533 | 0.230 |
Why?
|
| Middle Aged | 24 | 2024 | 220584 | 0.220 |
Why?
|
| Female | 29 | 2024 | 392148 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3088 | 0.210 |
Why?
|
| Mesalamine | 1 | 2023 | 135 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3209 | 0.200 |
Why?
|
| Humans | 40 | 2024 | 760617 | 0.200 |
Why?
|
| Male | 27 | 2024 | 360358 | 0.200 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2022 | 80 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 15828 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 20556 | 0.180 |
Why?
|
| Aged | 16 | 2024 | 169042 | 0.170 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 411 | 0.170 |
Why?
|
| Anorexia | 1 | 2020 | 154 | 0.170 |
Why?
|
| Logistic Models | 6 | 2019 | 13245 | 0.170 |
Why?
|
| United States | 10 | 2023 | 72272 | 0.160 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 426 | 0.160 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 159 | 0.160 |
Why?
|
| Ferritins | 1 | 2021 | 597 | 0.150 |
Why?
|
| Nausea | 1 | 2020 | 679 | 0.140 |
Why?
|
| Adult | 19 | 2024 | 220969 | 0.140 |
Why?
|
| Cholecystectomy | 1 | 2019 | 406 | 0.140 |
Why?
|
| Vomiting | 1 | 2020 | 651 | 0.140 |
Why?
|
| Pancreatin | 1 | 2016 | 9 | 0.140 |
Why?
|
| Risk Factors | 6 | 2023 | 74115 | 0.130 |
Why?
|
| Patient Discharge | 2 | 2019 | 3442 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2020 | 41457 | 0.130 |
Why?
|
| Sex Distribution | 1 | 2021 | 2278 | 0.130 |
Why?
|
| Hospitals | 2 | 2023 | 3877 | 0.130 |
Why?
|
| Cecum | 1 | 2016 | 233 | 0.130 |
Why?
|
| Age Distribution | 1 | 2021 | 2871 | 0.120 |
Why?
|
| Cathartics | 1 | 2016 | 127 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2021 | 991 | 0.120 |
Why?
|
| Pain Measurement | 1 | 2024 | 3546 | 0.110 |
Why?
|
| Clinical Audit | 1 | 2013 | 29 | 0.110 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2013 | 47 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 36402 | 0.110 |
Why?
|
| Urolithiasis | 1 | 2015 | 125 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2018 | 1185 | 0.110 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2013 | 41 | 0.110 |
Why?
|
| Indomethacin | 1 | 2013 | 323 | 0.110 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 6925 | 0.100 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 217 | 0.100 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2013 | 177 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2014 | 850 | 0.090 |
Why?
|
| Canada | 2 | 2013 | 2118 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 510 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2016 | 835 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 1669 | 0.090 |
Why?
|
| Time Factors | 3 | 2020 | 39913 | 0.080 |
Why?
|
| Medicaid | 1 | 2023 | 2814 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 3822 | 0.080 |
Why?
|
| Medicare | 2 | 2019 | 6765 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 7798 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 802 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 530 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 708 | 0.080 |
Why?
|
| Demography | 1 | 2013 | 1643 | 0.080 |
Why?
|
| Pregnancy | 2 | 2024 | 29868 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3410 | 0.070 |
Why?
|
| Prognosis | 3 | 2020 | 29600 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 741 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10754 | 0.070 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 939 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 1453 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3196 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 58894 | 0.060 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2005 | 54 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 22148 | 0.060 |
Why?
|
| RNA Helicases | 1 | 2005 | 143 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2014 | 2595 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 91 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2020 | 23972 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 5430 | 0.050 |
Why?
|
| Ataxia | 1 | 2005 | 306 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 2149 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 17878 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 18381 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4533 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 2238 | 0.050 |
Why?
|
| Neoplasms | 2 | 2023 | 22131 | 0.050 |
Why?
|
| Sepsis | 1 | 2015 | 2585 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8645 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2012 | 2495 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 59179 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2005 | 2700 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 26180 | 0.040 |
Why?
|
| Medical Audit | 1 | 2017 | 453 | 0.030 |
Why?
|
| Incidence | 1 | 2014 | 21337 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5367 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 15251 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 209 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 20988 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 88234 | 0.030 |
Why?
|
| Administration, Rectal | 1 | 2013 | 70 | 0.030 |
Why?
|
| Cost Savings | 1 | 2019 | 912 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2016 | 387 | 0.030 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2013 | 46 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 2013 | 152 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2023 | 1187 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 1610 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2023 | 1937 | 0.020 |
Why?
|
| Poverty | 1 | 2023 | 2692 | 0.020 |
Why?
|
| Survival Rate | 2 | 2016 | 12719 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2016 | 2635 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2024 | 54360 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2013 | 548 | 0.020 |
Why?
|
| Pancreas | 1 | 2016 | 1690 | 0.020 |
Why?
|
| Research Design | 1 | 2024 | 6174 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 568 | 0.020 |
Why?
|
| Mammography | 1 | 2019 | 2430 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 14591 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 1790 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2756 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 1467 | 0.020 |
Why?
|
| Phenotype | 1 | 2024 | 16571 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2019 | 2361 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 992 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9643 | 0.020 |
Why?
|
| Quebec | 1 | 2005 | 140 | 0.020 |
Why?
|
| Apraxias | 1 | 2005 | 59 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2013 | 2241 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2005 | 222 | 0.010 |
Why?
|
| Self Report | 1 | 2016 | 3723 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 3527 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2013 | 2160 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2270 | 0.010 |
Why?
|
| Leucine | 1 | 2005 | 548 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2024 | 64568 | 0.010 |
Why?
|
| Mass Screening | 1 | 2019 | 5424 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2005 | 535 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14648 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2506 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3742 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7389 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3680 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9604 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 933 | 0.010 |
Why?
|
| Recurrence | 1 | 2013 | 8426 | 0.010 |
Why?
|
| Sex Factors | 1 | 2015 | 10548 | 0.010 |
Why?
|
| Critical Illness | 1 | 2013 | 2709 | 0.010 |
Why?
|
| Lysine | 1 | 2005 | 993 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 30016 | 0.010 |
Why?
|
| Comorbidity | 1 | 2015 | 10505 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 1253 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 1994 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2005 | 851 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2005 | 1175 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10199 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 12966 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4110 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 26049 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 11106 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 36152 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 42188 | 0.010 |
Why?
|
| Child | 1 | 2015 | 80079 | 0.000 |
Why?
|